MBRX Stock Price, Moleculin Biotech Inc Quote, Chart

Market Summary

USD5.02-0.13

Market Closed

-2.52%

MBRX Stock Price

View Fullscreen

MBRX RSI Chart

MBRX Valuation

Market Cap

745.5K

Price/Earnings (Trailing)

-0.03

EV/EBITDA

1.35

Price/Free Cashflow

-0.03

MarketCap/EBT

-0.04

MBRX Price/Sales (Trailing)

MBRX Profitability

Return on Equity

-114.18%

Return on Assets

-77.89%

Free Cashflow Yield

-3.2K%

MBRX Fundamentals

MBRX Earnings

Earnings (TTM)

-29.8M

Earnings Growth (Yr)

-51.68%

Earnings Growth (Qtr)

-83.08%

Breaking Down MBRX Revenue

Last 7 days

8.4%

Last 30 days

-4.4%

Last 90 days

884.3%

Trailing 12 Months

543.6%

How does MBRX drawdown profile look like?

MBRX Financial Health

Current Ratio

3.86

MBRX Investor Care

Buy Backs (1Y)

92.22%

Tracking the Latest Insider Buys and Sells of Moleculin Biotech Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 26, 2023	george robert e.	bought	10,000	0.69	14,493	-
Dec 26, 2023	foster jonathan p.	bought	20,000	0.69	28,986	chief financial officer
Dec 26, 2023	klemp walter v	bought	129,999	0.69	188,404	ceo and president
Jul 11, 2023	klemp walter v	sold (taxes)	-1,898	0.5903	-3,216	ceo and president
Jul 11, 2023	klemp walter v	acquired	-	-	13,204	ceo and president
Jul 02, 2023	klemp walter v	sold (taxes)	-2,074	0.5788	-3,584	ceo and president
Jul 02, 2023	klemp walter v	acquired	-	-	14,717	ceo and president
Jun 20, 2023	foster jonathan p.	acquired	-	-	40,667	chief financial officer
Jun 20, 2023	klemp walter v	acquired	-	-	56,250	ceo and president
Jun 20, 2023	klemp walter v	sold (taxes)	-7,807	0.57	-13,697	ceo and president

Which funds bought or sold MBRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	Sigma Planning Corp	sold off	-100	-10,301	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	JMAC ENTERPRISES LLC	sold off	-100	-11,273	-	-%
Apr 30, 2024	North Star Investment Management Corp.	sold off	-100	-215	-	-%
Apr 30, 2024	North Star Investment Management Corp.	new	-	95.00	95.00	-%
Apr 29, 2024	HAZLETT, BURT & WATSON, INC.	sold off	-100	-	-	-%
Apr 26, 2024	SCHMIDT P J INVESTMENT MANAGEMENT INC	sold off	-100	-14,094	-	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	new	-	4,048	4,048	-%
Apr 17, 2024	ATTICUS WEALTH MANAGEMENT, LLC	sold off	-100	-42,921	-	-%

Are Funds Buying or Selling MBRX?

Are funds buying MBRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MBRX

No. of Funds

Unveiling Moleculin Biotech Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	3,316,221	SC 13G
Feb 10, 2021	vanguard group inc	0.95%	591,954	SC 13G/A
Jan 20, 2021	empery asset management, lp	4.57%	2,990,053	SC 13G/A
Jan 04, 2021	sabby management, llc	4.99%	3,116,982	SC 13G/A
Nov 13, 2020	lincoln park capital fund, llc	7.52%	4,787,254	SC 13G
Feb 11, 2020	vanguard group inc	5.69%	2,602,114	SC 13G
Feb 11, 2020	empery asset management, lp	7.05%	3,750,000	SC 13G
Feb 10, 2020	cvi investments, inc.	3.8%	1,800,000	SC 13G/A
Feb 07, 2020	sabby management, llc	7.05%	3,750,000	SC 13G
Jan 08, 2020	sabby management, llc	4.99%	2,281,812	SC 13G/A

Recent SEC filings of Moleculin Biotech Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	8-K	Current Report
Apr 26, 2024	10-K/A	Annual Report
Apr 25, 2024	8-K	Current Report
Apr 18, 2024	8-K	Current Report
Apr 10, 2024	8-K	Current Report
Apr 08, 2024	8-K	Current Report
Mar 27, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 22, 2024	10-K	Annual Report

Peers (Alternatives to Moleculin Biotech Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Moleculin Biotech Inc News

Latest updates

Moleculin Biotech Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.3%	38,217	39,523	47,115	51,062	57,422	65,372	73,255	78,801	84,090	88,702	93,534	99,784	29,031	27,144	31,380	25,472	25,235	30,398	31,854	21,298	19,585
Current Assets	-4.8%	26,273	27,603	35,380	39,289	45,596	53,493	61,322	67,260	72,497	77,070	81,836	88,019	17,198	15,250	19,749	13,787	13,484	18,586	20,202	9,613	7,974
Cash Equivalents	-4.2%	23,550	24,579	32,172	37,300	43,145	50,392	57,999	66,104	70,903	75,178	79,506	86,293	15,173	12,795	16,734	11,649	10,735	15,409	18,695	8,782	7,134
Net PPE	20.9%	272	225	229	244	275	306	339	312	338	353	395	438	483	522	238	271	316	358	401	431	463
Liabilities	176.9%	12,144	4,385	6,847	5,378	5,231	6,955	6,896	6,136	5,097	7,443	8,834	11,268	11,271	12,677	15,751	10,180	9,664	11,423	9,762	6,616	5,313
Current Liabilities	75.3%	6,815	3,888	6,554	5,032	4,819	6,362	5,859	4,834	3,622	3,656	3,350	4,578	2,920	3,438	3,739	3,235	3,570	11,119	9,591	6,436	3,878
Shareholder's Equity	-25.8%	26,073	35,138	40,268	45,684	52,191	58,417	66,359	72,665	78,993	81,259	84,700	88,516	17,760	14,467	15,629	15,292	15,571	18,975	22,092	14,682	14,272
Retained Earnings	-8.5%	-131,604	-121,300	-115,726	-109,750	-101,835	-95,065	-86,454	-79,677	-72,810	-69,984	-65,605	-61,361	-56,916	-54,277	-50,900	-40,800	-39,561	-35,763	-31,600	-30,400	-26,356
Additional Paid-In Capital	0.8%	157,653	156,446	155,957	155,396	153,985	153,450	152,762	152,260	151,733	151,175	150,231	149,788	74,671	68,649	66,428	56,011	55,055	54,673	53,643	45,021	40,564
Accumulated Depreciation	-	896	-	-	-	769	-	-	-	638	-	-	-	474	-	-	-	284	-	-	-	93.00
Shares Outstanding	-92.5%	149	1,987	1,986	1,973	-	1,906	1,906	1,905	1,905	1,754	1,897	1,896	-	-	-	-	-	-	-	-	-
Float	-	-	-	16,000	-	-	-	40,000	-	-	-	101,000	-	-	-	52,000	-	-	-	48,000	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	28.4%	-5,407	-7,551	-5,126	-6,017	-7,256	-7,577	-8,001	-4,805	-4,300	-4,295	-6,805	-3,600	-3,124	-5,347	-5,000	-4,300	-4,677	-3,327	-5,347	-3,847	-3,110
Share Based Compensation	-2.8%	479	493	513	499	535	699	514	527	556	979	433	405	415	460	408	397	382	489	318	348	315
Cashflow From Investing	-189.3%	-81.00	-28.00	-15.00	-	-	-	-61.00	-6.00	-19.00	-	-	-	-14.00	-340	-18.00	-2.00	-9.00	-8.00	-19.00	-15.00	-114
Cashflow From Financing	111725.0%	4,465	-4.00	49.00	141	-	-11.00	-12.00	-	-	-24.00	-	74,748	5,484	1,762	10,012	5,291	-	52.00	15,281	5,521	1,761

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MBRX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 0	$ 0
Operating expenses:
Research and development	19,487,000	18,968,000
General and administrative	10,017,000	11,542,000
Depreciation and amortization	127,000	130,000
Total operating expenses	29,631,000	30,640,000
Loss from operations	(29,631,000)	(30,640,000)
Other income:
(Loss) gain from change in fair value of warrant liability	(1,044,000)	1,335,000
Transaction costs allocated to warrant liabilities	(510,000)	0
Other income, net	48,000	40,000
Interest income, net	1,368,000	240,000
Net loss	$ (29,769,000)	$ (29,025,000)
Net loss per common share - basic and diluted (in dollars per share)	$ (15.07)	$ (15.22)
Weighted average common shares outstanding, basic and diluted (in shares)	1,975,610	1,906,960
Comprehensive loss:
Net loss	$ (29,769,000)	$ (29,025,000)
Other comprehensive (loss) income:
Foreign currency translation	(21,000)	(29,000)
Comprehensive loss	$ (29,790,000)	$ (29,054,000)

MBRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 23,550	$ 43,145
Prepaid expenses and other current assets	2,723	2,451
Total current assets	26,273	45,596
Furniture and equipment, net of accumulated depreciation of $896 and $769, respectively	272	275
Intangible assets	11,148	11,148
Operating lease right-of-use asset	524	403
Total Assets	38,217	57,422
Current Liabilities:
Accounts payable	2,498	2,095
Accrued expenses and other current liabilities	4,317	2,724
Total current liabilities	6,815	4,819
Operating lease liability - long-term, net of current portion	474	335
Warrant liability - long-term	4,855	77
Total Liabilities	12,144	5,231
Commitments and contingencies (Note 8)
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 authorized, no shares issued and outstanding	0	0
Common stock, $0.001 par value; 100,000,000 authorized as of December 31, 2023 and December 31, 2022, 2,227,516 and 1,908,523 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	33	29
Additional paid-in capital	157,653	153,985
Accumulated other comprehensive (loss) income	(9)	12
Accumulated deficit	(131,604)	(101,835)
Total stockholders' equity	26,073	52,191
Total liabilities and stockholders' equity	$ 38,217	$ 57,422

About Moleculin Biotech Inc

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

CEO	Mr. Walter V. Klemp
WEBSITE	moleculin.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Moleculin Biotech Inc Frequently Asked Questions

What is the ticker symbol for Moleculin Biotech Inc? What does MBRX stand for in stocks?

MBRX is the stock ticker symbol of Moleculin Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Moleculin Biotech Inc (MBRX)?

As of Fri May 03 2024, market cap of Moleculin Biotech Inc is 745.48 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MBRX stock?

You can check MBRX's fair value in chart for subscribers.

What is the fair value of MBRX stock?

You can check MBRX's fair value in chart for subscribers. The fair value of Moleculin Biotech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Moleculin Biotech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MBRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Moleculin Biotech Inc a good stock to buy?

The fair value guage provides a quick view whether MBRX is over valued or under valued. Whether Moleculin Biotech Inc is cheap or expensive depends on the assumptions which impact Moleculin Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBRX.